Ассоциации адипокинов с ишемической болезнью сердца у людей молодого и среднего возраста

Целью данного обзора являлось найти ответ на вопрос: «Существует ли ассоциация адипокинов (адипонектин, адипсин, интерлейкин-6, липокалин-2, PAI-1, резистин, MCP-1, лептин, TNF-α, висфатин, оментин-1) с ишемической болезнью сердца (ИБС) и абдоминальным ожирением у лиц до 65 лет?». В анализ включались публикации последних 10 лет (2013–2023 гг.), в которых исследовались больные ИБС в возрасте от 18 до 65 лет. Обнаружено, что крупные исследования и метаанализы указывают на большой вклад адипоцитокинов в развитие и течение ИБС. Исходя из этого, весьма актуальным представляется изучение адипоцитокинового профиля у людей молодого и среднего возраста с ИБС, особенно на фоне абдоминального ожирения.

1. Шальнова С.А., Конради А.О., Карпов Ю.А., Концевая А.В., Деев А.Д., Капустина А.В., Худяков М.Б., Шляхто Е.В., Бойцов С.А. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечнососудистых заболеваний в различных регионах России». Рос. кардиол. журн., 2012; 5: 6–11.

2. Научно-организационный комитет проекта ЭССЕРФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилакт. медицина, 2013; 16 (6): 25–34.

3. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Рос. кардиол. журн., 2018; 6: 7–122. doi: 10.15829/1560-4071-20186-7-122

4. Ural D., Kiliçkap M., Göksülük H., Karaaslan D., Kayikçioǧlu M., Özer N., Barçin C., Yilmaz M.B., Abaci A., Şengül Ş., Arinsoy T., Erdem Y., Sanisoǧlu Y., Şahin M., Tokgözoǧlu L. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars., 2018; 46: 577–590. doi: 10.5543/tkda.2018.62200

5. Побожева И.А., Разгильдина Н.Д., Полякова Е.А., Пантелеева А.А., Беляева О.Д., Нифонтов С.Е., Галкина О.В., Колодина Д.А., Беркович О.А., Баранова Е.И., Пчелина С.Н., Мирошникова В.В. Экспрессия гена адипонектина в эпикардиальной и подкожной жировой ткани при ишемической болезни сердца. Кардиология, 2020; 60 (4): 62–69. doi: 10.18087/cardio.2020.4.n517

6. Picard F.A., Gueret P., Laissy J.P., Champagne S., Leclercq F., Carrié D., Juliard J.M., Henry P., Niarra R., Chatellier G., Steg P.G. Epicardial Adipose Tissue Thickness Correlates with the Presence and Severity of Angiographic Coronary Artery Disease in Stable Patients with Chest Pain. PLoS ONE, 2014; 9 (10): e110005. doi: 10.1371/journal.pone.0110005

7. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Рос. кардиол. журн., 2020; 25 (11): 4076. doi: 10.15829/1560-4071-20204076

8. Петренко Ю.В., Герасимова К.С., Новикова В.П. Биологическая и патофизиологическая значимость адипонектина. Педиатр, 2019; 10 (2): 83–87. doi: 10.17816/PED10283-87

9. Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., Yeh J., Best L.G. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 2005; 25 (3): e15– e16. doi: 10.1161/01.ATV.0000153090.21990.8c

10. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., Danesh J., Whincup P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006; 114 (7): 623–629. doi: 10.1161/CIRCULATIONAHA.106.618918

11. Diah M., Lelo A., Lindarto D., Mukhtar Z. Plasma Concentrations of Adiponectin in Patients with Coronary Artery Disease and Coronary Slow Flow. Acta Med. Indones, 2019; 51 (4): 290–295.

12. Полякова Е.А. Низкий уровень адипонектина в крови как фактор риска тяжелого течения ишемической болезни сердца. Атеросклероз и дислипидемии, 2022; 1 (46): 47–56. doi: 10.34687/22198202.JAD.2022.01.0005

13. Hao G., Li W., Guo R., Yang J.G., Wang Y., Tian Y., Liu M.Y., Peng Y.G., Wang Z.W. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis, 2013; 228 (1): 29–35. doi: 10.1016/j.atherosclerosis.2013.02.018

14. Sook Lee E., Park S.S., Kim E., Sook Yoon Y., Ahn H.Y., Park C.Y., Ho Yun Y., Woo Oh.S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and metaanalysis. Int. J. Epidemiol., 2013; 42 (4): 1029–1039. doi: 10.1093/ije/dyt087

15. Wannamethee S.G., Welsh P., Whincup P.H., Sawar N., Thomas M.C., Gudnarsson V., Sattar N. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur. J. Cardiovasc. Prev. Rehabil., 2011; 18 (1): 65–71. doi: 10.1097/HJR.0b013e32833b09d9

16. Yang L., Li B., Zhao Y., Zhang Z. Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis. Lipids Health Dis., 2019; 18 (1): 227. doi: 10.1186/s12944019-1168-3

17. Lo J.C., Ljubicic S., Leibiger B., Kern M., Leibiger I.B., Moede T., Kelly M.E., Chatterjee Bhowmick D., Murano I., Cohen P., Banks A.S., Khandekar M.J., Dietrich A., Flier J.S., Cinti S., Blüher M., Danial N.N., Berggren P.O., Spiegelman B.M. Adipsin is an adipokine that improves β cell function in diabetes. Cell, 2014; 158 (1): 41–53. doi: 10.1016/j.cell.2014.06.005

18. Василенко М.А., Кириенкова Е.В., Скуратовская Д.А. Затолокин П.А, Миронюк Н.И., Литвинова Л.С. Роль продукции адипсина и лептина в формировании инсулинорезистентности у больных абдоминальным ожирением. Докл. АН, 2017; 475 (3): 336–341. doi: 10.7868/S0869565217210228

19. Ohtsuki T., Satoh K., Shimizu T., Ikeda S., Kikuchi N., Satoh T., Kurosawa R., Nogi M., Sunamura S., Yaoita N., Omura J., Aoki T., Tatebe S., Sugimura K., Takahashi J., Miyata S., Shimokawa H. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. J. Am. Heart Assoc., 2019; 8 (23): e013716. doi: 10.1161/jAHA.119.013716

20. Sun R., Qiao Y., Yan G., Wang D., Zuo W., Ji Z., Zhang X., Yao Y., Ma G., Tang C. Association between serum adipsin and plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease. J. Thorac. Dis., 2021; 13 (4): 2414–2425. doi: 10.21037/jtd-21-259

21. Рагино Ю.И., Щербакова Л.В., Облаухова В.И., Полонская Я.В., Стахнева Е.М., Кузьминых Н.А., Каштанова Е.В. Адипокины крови у молодых людей с ранней ишемической болезнью сердца на фоне абдоминального ожирения. Кардиология, 2021; 61 (4): 32–38. doi: 10.18087/cardio.2021.4.n1369

22. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried S.K., Gong D.W., Shuldiner A.R., Pollin T.I., McLenithan J.C. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56 (6): 1655–1661. doi: 10.2337/db06-1506

23. Bai P., Abdullah F., Lodi M., Sarhadi M., Dilip A., Shahab S., Yasir F., Jahangir M. Association Between Coronary Artery Disease and Plasma Omentin-1 Levels. Cureus, 2021; 13 (8): e17347. doi: 10.7759/cureus.17347

24. Onur I., Oz F., Yildiz S., Oflaz H., Sigirci S., Elitok A., Pilten S., Karaayvaz E.B., Cizgici A.Y., Kaya M.G., Onur S.T., Sahin I., Dinckal H.M. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology, 2014; 65 (10): 896–900. doi: 10.1177/0003319713511322

25. Matloch Z., Kratochvílová H., Cinkajzlová A., Kopecký P., Pořízka M., Haluzíková D., Lindner J., Mráz M., Kloučková J., Lacinová Z., Haluzík M. Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease. Physiol. Res., 2018; 67 (6): 881–890. doi: 10.33549/physiolres.933909

26. Baig M., Alghalayini K.W., Gazzaz Z.J., Atta H. Association of Serum Omentin-1, Chemerin, and Leptin with Acute Myocardial Infarction and its Risk Factors. Pak. J. Med. Sci., 2020; 36 (6): 1183–1188. doi: 10.12669/pjms.36.6.2372

27. Zhou J.P., Tong X.Y., Zhu L.P., Luo J.M., Luo Y., Bai Y.P., Li C.C., Zhang G.G. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J. Atheroscler. Thromb., 2017; 24 (9): 940–948. doi: 10.5551/jat.37440

28. Saely C.H., Leiherer A., Muendlein A., Vonbank A., Rein P., Geiger K., Malin C., Drexel H. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief., 2015; 6: 158–161. doi: 10.1016/j.dib.2015.11.065

29. Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J. Am. Coll. Cardiol., 2018; 71 (20): 2360–2372. doi: 10.1016/j.jacc.2018.03.509

30. Dahl T.B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., Damås J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S.S., Krohg-Sørensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 2007; 115 (8): 972–80. doi: 10.1161/CIRCULATIONAHA.106.665893

31. Xu F., Ning X., Zhao T., Lu Q., Chen H. Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose. Open Med. (Wars), 2022; 17 (1): 1405–1411. doi: 10.1515/med2022-0540

32. Wang X.H., Dou L.Z., Gu C., Wang X.Q. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac. J. Trop. Med., 2014; 7 (1): 55–62. doi: 10.1016/S19957645(13)60192-3

33. Zheng M., Lu N., Ren M., Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC Cardiovasc. Disord., 2020; 20 (1): 271. doi: 10.1186/s12872-020-01549-3

34. Wu X.A., Xie G., Li X.Q., Wu H.T., Wang X. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents. Clin. Chim. Acta, 2018; 479: 20–24. doi: 10.1016/j.cca.2018.01.004

35. Yu F., Li J., Huang Q., Cai H. Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies. Angiology, 2018; 69 (9): 825–834. doi: 10.1177/0003319718771125

36. Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol., 2021; 101: 107598. doi: 10.1016/j.intimp.2021.107598

37. Bremer A.A., Devaraj S., Afify A., Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab., 2011; 96 (11): E1782–E1788. doi: 10.1210/jc.2011-1577

38. Arner E., Mejhert N., Kulyté A., Balwierz P.J., Pachkov M., Cormont M., Lorente-Cebrián S., Ehrlund A., Laurencikiene J., Hedén P., Dahlman-Wright K., Tanti J.F., Hayashizaki Y., Rydén M., Dahlman I., van Nimwegen E., Daub C.O., Arner P. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes, 2012; 61 (8): 1986–1993. doi: 10.2337/db11-1508

39. Fuchs S., Lavi I., Tzang O., Bessler H., Brosh D., Bental T., Dvir D., Einav S., Kornowski R. Intracoronary monocyte chemoattractant protein 1 and vascular endothelial growth factor levels are associated with necrotic core, calcium and fibrous tissue atherosclerotic plaque components: an intracoronary ultrasound radiofrequency study. Cardiology, 2012; 123 (2): 125–132. doi: 10.1159/000342050

40. Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., Ruotolo G., Luzi L., Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care, 2009; 32 (11): 2105–2110. doi: 10.2337/dc09-0763

41. Bianconi V., Sahebkar A., Atkin S.L., Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr. Opin. Hematol., 2018; 25 (1): 44– 51. doi: 10.1097/MOH.0000000000000389

42. Schneiderman J., Sawdey M.S., Keeton M.R., Bordin G.M., Bernstein E.F., Dilley R.B., Loskutoff D.J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. U. S. A., 1992; 89 (15): 6998–7002. doi: 10.1073/pnas.89.15.6998

43. Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc. Ther., 2010; 28 (5): e72–e91. doi: 10.1111/j.1755-5922.2010.00171.x

44. Orenes-Piñero E., Pineda J., Roldán V., Hernández-Romero D., Marco P., Tello-Montoliu A., Sogorb F., Valdés M., Lip G.Y., Marín F. Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. J. Atheroscler. Thromb., 2015; 22 (6): 610–617. doi: 10.5551/jat.26161

45. Chen R., Yan J., Liu P., Wang Z., Wang C. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab. Brain. Dis., 2017; 32 (3): 667–673. doi: 10.1007/s11011-017-0007-3

46. Tschoner A., Sturm W., Engl J., Kaser S., Laimer M., Laimer E., Klaus A., Patsch J.R., Ebenbichler C.F. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr. Metab. Cardiovasc. Dis., 2012; 22 (4): 340–346. doi: 10.1016/j.numecd.2010.07.009

47. Barnard S.A., Pieters M., Nienaber-Rousseau C., Kruger H.S. Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women. Thromb. Res., 2016; 146: 95–102. doi: 10.1016/j.thromres.2016.09.003

48. Barbato A., Iacone R., Tarantino G., Russo O., Sorrentino P., Avallone S., Galletti F., Farinaro E., Della Valle E., Strazzullo P. Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern. Emerg. Med., 2009; 4 (4): 315–323. doi: 10.1007/s11739-009-0240-9

49. Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L., Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism, 1990; 39 (10): 1044–1048. doi: 10.1016/0026-0495(90)90164-8

50. Bilgic Gazioglu S., Akan G., Atalar F., Erten G. PAI1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients. Int. J. Clin. Exp. Pathol., 2015; 8 (12): 15919–15925. ISSN: 1936-2625

51. Shimizu T., Uematsu M., Yoshizaki T., Obata J.E., Nakamura T., Fujioka D., Watanabe K., Watanabe Y., Kugiyama K. Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction. J. Atheroscler. Thromb., 2016; 23 (5): 557–566. doi: 10.5551/jat.32300

52. Liang Z., Jiang W., Ouyang M., Yang K. PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis. Int. J. Clin. Exp. Med., 2015; 8 (2): 2097–2107. ISSN: 1940-5901

53. Choi K.M., Lee J.S., Kim E.J., Baik S.H., Seo H.S., Choi D.S., Oh D.J., Park C.G. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol., 2008; 158 (2): 203–207. doi: 10.1530/EJE-07-0633

54. Ni J., Ma X., Zhou M., Pan X., Tang J., Hao Y., Lu Z., Gao M., Bao Y., Jia W. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc. Diabetol., 2013; 12: 176. doi: 10.1186/1475-2840-12-176

55. Li C., Zhang Z., Peng Y., Gao H., Wang Y., Zhao J., Pan C. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One, 2019; 14 (8): e0220841. doi: 10.1371/journal.pone.0220841

56. Shibata K., Sato K., Shirai R., Seki T., Okano T., Yamashita T., Koide A., Mitsuboshi M., Mori Y., Hirano T., Watanabe T. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. Heart Vessels, 2020; 35 (7): 1012–1024. doi: 10.1007/s00380-020-01556-6

57. Oberoi R., Bogalle E.P., Matthes L.A., Schuett H., Koch A.K., Grote K., Schieffer B., Schuett J., Luchtefeld M. Lipocalin (LCN) 2 Mediates Pro-Atherosclerotic Processes and Is Elevated in Patients with Coronary Artery Disease. PLoS One, 2015; 10 (9): e0137924. doi: 10.1371/journal.pone.0137924

58. Soylu K., Aksan G., Nar G., Özdemir M., Gülel O., İnci S., Aksakal A., Soylu Aİ., Yılmaz Ö. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol. J. Cardiol., 2015; 15 (6): 450–455. doi: 10.5152/akd.2014.5513

59. Lahiri A., Alex A.G., George P.V. Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes. Indian. Heart J., 2018; 70 (2): 220–224. doi: 10.1016/j.ihj.2017.06.005

60. Chen Y., Fu Y., Wang S., Chen P., Pei Y., Zhang J., Zhang R., Niu G., Gu F., Li X. Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥ 65 years. Cardiovasc. Diabetol., 2022; 21 (1): 252. doi: 10.1186/s12933-02201668-5

61. Peng W., Zhang C., Wang Z., Yang W., Luo H., Li X., Fu D., Yu C., Zhou Y. Prognostic value of neutrophil gelatinase-associated lipocalin and glycosylated hemoglobin for non-ST-segment elevation myocardial infarction patients with single concomitant chronic total occlusion following primary percutaneous coronary intervention: A prospective observational study. Medicine (Baltimore), 2019; 98 (39): e16982. doi: 10.1097/MD.0000000000016982

62. Kim M., Oh J.K., Sakata S., Liang I., Park W., Hajjar R.J., Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J. Mol. Cell Cardiol., 2008; 45 (2): 270–280. doi: 10.1016/j.yjmcc.2008.05.006

63. Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mech. Ageing. Dev., 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004

64. Тепляков А.Т., Ахмедов Ш.Д., Суслова Т.Е., Андриянова А.В., Кузнецова А.В., Протопопова Н.В., Калюжин В.В., Насанова О.Н. Влияние резистина на течение ишемической болезни сердца у пациентов с сахарным диабетом 2-го типа. Бюл. сиб. мед., 2015; 14 (5): 73–82. doi: 10.20538/16820363-2015-5-73-82

65. Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak. J. Med. Sci., 2019; 35(3): 641–646. doi:10.12669/pjms.35.3.274

66. Заковряшина И.Н., Хаишева Л.А., Шлык С.В. Изучение уровня резистина и липидного профиля у пациентов с инфарктом миокарда с подъемом сегмента ST, результаты годового наблюдения. Атеросклероз и дислипидемии, 2022; 4 (45): 51–58. doi: 10.34687/2219-8202.JAD.2021.04.0006

67. Авсарагова А.З., Астахова З.Т., Ремизов О.В. Влияние адипокина резистина на риск развития сердечно-сосудистых осложнений у больных острым коронарным синдромом. Вестн. новых мед. технологий, 2019; 4: 49–52. doi: 10.24411/1609-2163-201916513

68. Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin is increased in patients with unstable angina. Chin. Med. J. (Engl). 2007; 120 (10): 871–875.

69. On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ. J., 2007; 71 (6): 868–873. doi: 10.1253/circj.71.868

70. Zhang J.Z., Gao Y., Zheng Y.Y., Liu F., Yang Y.N., Li X.M., Ma X., Ma Y.T., Xie X. Increased serum resistin level is associated with coronary heart disease. Oncotarget, 2017; 8 (30): 50148–50154. doi: 10.18632/oncotarget

71. Chen D., Zhang Y., Yidilisi A., Xu Y., Dong Q., Jiang J. Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study. J. Clin. Endocrinol. Metab., 2022; 107 (6): e2572–e2580. doi: 10.1210/clinem/dgac048

72. Mauer J., Denson J.L., Bruning J.C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol., 2015: 36 (2): 92–101 doi: 10.1016/j.it.2014.12.008

73. Mauer J., Chaurasia B., Goldau J., Vogt M.C., Ruud J., Nguyen K.D. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol., 2014; 15 (5): 423–430. doi: 10.1038/ni.2865

74. Yaseen F., Jaleel A., Aftab J., Zuberi A., Alam E. Circulating levels of resistin, IL-6 and lipid profile in elderly patients with ischemic heart disease with and without diabetes. Biomark Med., 2012; 6 (1): 97–102. doi: 10.2217/bmm.11.104

75. Cheng K.H., Chu C.S., Lee K.T., Lin T.H., Hsieh C.C., Chiu C.C., Voon W.C., Sheu S.H., Lai W.T. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int. J. Obes. (Lond), 2008; 32 (2): 268–274. doi: 10.1038/sj.ijo.0803726

76. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA, 2002; 288 (8): 980–987. doi: 10.1001/jama.288.8.980

77. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., Mabuchi N., Sawaki M., Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol., 1998; 31 (2): 391–398. doi: 10.1016/s0735-1097(97)00494-4

78. Tajfard M., Latiff L.A., Rahimi H.R., Moohebati M., Hasanzadeh M., Emrani A.S., Esmaeily H., Taghipour A., Mirhafez S.R., Ferns G.A., Mardan-Nik M., Mohammadzadeh E., Avan A., Hanachi P., Ghayour-Mobarhan M. Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography. Mol. Cell Biochem., 2017; 435 (1-2): 37–45. doi: 10.1007/s11010-0173054-5

79. Antonopoulos A.S., Angelopoulos A., Papanikolaou P., Simantiris S., Oikonomou E.K., Vamvakaris K., Koumpoura A., Farmaki M., Trivella M., Vlachopoulos C., Tsioufis K., Antoniades C., Tousoulis D. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC Cardiovasc. Imaging., 2022; 15 (3): 460–471. doi: 10.1016/j.jcmg.2021.09.014

80. Kaptoge S., Seshasai S.R., Gao P., Freitag D.F., Butterworth A.S., Borglykke A., di Angelantonio E., Gudnason V., Rumley A., Lowe G.D., Jørgensen T., Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur. Heart J., 2014; 35 (9): 578–589. doi: 10.1093/eurheartj/eht367

81. Blum W.F., Englaro P., Hanitsch S., Juul A., Hertel N.T., Müller J., Skakkebaek N.E., Heiman M.L., Birkett M., Attanasio A.M., Kiess W., Rascher W. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J. Clin. Endocrinol. Metab., 1997; 82 (9): 2904–2910. doi: 10.1210/jcem.82.9.4251

82. Bigalke B., Stellos K., Geisler T., Seizer P., Mozes V., Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets, 2010; 21 (1): 11–19. doi: 10.3109/09537100903377584

83. Anagnostoulis S., Karayiannakis A.J., Lambropoulou M., Efthimiadou A., Polychronidis A, Simopoulos C. Human leptin induces angiogenesis in vivo. Cytokine, 2008; 42 (3): 353–357. doi: 10.1016/j.cyto.2008.03.009

84. Chai S.B., Sun F., Nie X.L., Wang J. Leptin and coronary heart disease: a systematic review and meta-analysis. Atherosclerosis, 2014; 233 (1): 3–10. doi: 10.1016/j.atherosclerosis.2013.11.069

85. Yang H., Guo W., Li J., Cao S., Zhang J., Pan J., Wang Z., Wen P., Shi X., Zhang S. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. PLoS One, 2017; 12 (3): e0166360. doi: 10.1371/journal.pone.0166360

86. Zeng R., Xu C.H., Xu Y.N., Wang Y.L., Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq. Bras. Endocrinol. Metabol., 2014; 58 (8): 817– 823. doi: 10.1590/0004-2730000003390

87. Rahmani A., Toloueitabar Y., Mohsenzadeh Y. Hemmati R., Sayehmiri K., Asadollahi K. Association between plasma leptin/adiponectin ratios with the extent and severity of coronary artery disease. BMC Cardiovasc. Disord., 2020; 20 (1): 474. doi: 10.1186/s12872020-01723-7

88. Полякова Е.А. Роль растворимых рецепторов лептина в патогенезе ишемической болезни сердца. Регионарное кровообращение и микроциркуляция, 2021; 20 (3): 34–45. doi: 10.24884/1682-6655-202120-3-34-45

89. Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы. Артериальная гипертензия, 2011; 17 (3): 203–208. doi: 10.18705/1607-419X-2011-173-203-208

90. Bergh N., Ulfhammer E., Glise K., Jern S., Karlsson L. Influence of TNF-alpha and biomechanical stress on endothelial antiand prothrombotic genes. Biochem. Biophys. Res. Commun., 2009; 385 (3): 314– 318. doi: 10.1016/j.bbrc.2009.05.046

91. Hu J., Liu X., Tang Y. HMGB1/Foxp1 regulates hypoxia-induced inflammatory response in macrophages. Cell Biol. Int., 2022; 46 (2): 265–277. doi: 10.1002/cbin.11728

92. Gonzálvez M., Ruiz-Ros J.A., Pérez-Paredes M., Lozano M.L., García-Almagro F.J., Martínez-Corbalán F., Giménez D.M., Carrillo A., Carnero A., Cubero T., Gonzálvez J.J., Ureña I., Vicente V. Valor pronóstico del factor de necrosis tumoral alfa en pacientes con infarto agudo de miocardio con elevación del segmento ST [Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev. Esp. Cardiol., 2007; 60 (12): 1233–1241. doi: 10.1157/13113928 (In Spanish)

93. Paccalet A., Crola Da Silva C., Mechtouff L., Amaz C., Varillon Y., de Bourguignon C., Cartier R., Prieur C., Tomasevic D., Genot N., Leboube S., Derimay F., Rioufol G., Bonnefoy-Cudraz E., Mewton N., Ovize M., Bidaux G., Bochaton T. Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction. Front. Pharmacol., 2021; 12: 656928. doi: 10.3389/fphar.2021.656928

94. Yuan S., Carter P., Bruzelius M., Vithayathil M., Kar S., Mason A.M., Lin A., Burgess S., Larsson S.C. Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine, 2020; 59: 102956. doi: 10.1016/j.ebiom.2020.102956